DERMA SCIENCES, INC. Form SC 13D/A March 22, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934 (Amendment No. 10)*

Derma Sciences, Inc.

(Name of Issuer)

Common Stock, \$0.01 par value

(Title of Class of Securities)

249827205

(CUSIP Number)
Raymond C. Hedger
Hedger & Hedger
2 Fox Chase Drive, P.O. Box 915, Hershey, PA 17033
(717)534-9993

(,1,,001 3330

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

January 31, 2005

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement of Schedule 13G to report the acquisition which is the subject of the Schedule 13D, and is filing this schedule because of ss. 240.13d-1(e), ss. 240.13d-1(f) or ss. 240.13d-1(g), check the following box [].

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7(b) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following page(s))

PAGE 2 CUSIP No. 249827205		Schedule 13D
1 NAME OF REPORTING PERS	SON CICATION NO. OF ABOVE PERSON	
Edward J. Quilty	101-42-3117	
2 CHECK THE APPROPRIATE	BOX IF A MEMBER OF A GROUP*	(a) [] (b) []
3 SEC USE ONLY		
4 SOURCE OF FUNDS* Not applicable		
5 CHECK BOX IF DISCI	JOSURE OF LEGAL PROCEEDINGS IS REQUIRED PU	JRSUANT TO
6 CITIZENSHIP OR PLACE (OF ORGANIZATION	
United States		
NUMBER OF SHARES	7 SOLE VOTING POWER	
BENEFICALLY	1,039,490	
OWNED BY EACH	8 SHARED VOTING POWER	
REPORTING		
PERSON WITH	9 SOLE DISPOSITIVE POWER	
	1,039,490	
	10 SHARED DISPOSITIVE POWER	
11 AGGREGATE AMOUNT BEN	EFICIALLY OWNED BY EACH REPORTING PERSON	
1,039,490		
	GREGATE AMOUNT IN ROW (11) EXCLUDES CERTA	 IN SHARES*
		[]
13 PERCENT OF CLASS REP	PRESENTED BY AMOUNT IN ROW (11)	
8.00%		
14 TYPE OF REPORTING PE		
IN		
*SEE	INSTRUCTIONS BEFORE FILLING OUT!	

PAGE 3 CUSIP No. 249827205

Schedule 13D

Item 1. Security and Issuer

This Schedule 13D relates to the common stock, \$.01 par value (the "Common Stock"), of Derma Sciences, Inc., a Pennsylvania corporation (the "Issuer"), whose principal executive offices are located at 214 Carnegie Center, Suite 100, Princeton, New Jersey 08540.

Item 2. Identity and Background

This Schedule 13D is being filed by Edward J. Quilty (the "Reporting Person"). Certain information with respect to the Reporting Person is set forth below:

Name and Address: Edward J. Quilty

214 Carnegie Center

Suite 100

Princeton, NJ 08540

Principal Occupation: Chairman of the Board of Directors, President

and Chief Executive Officer of the Issuer

Criminal convictions: None

Civil proceedings: None

Citizenship: United States

Item 3. Source and Amount of Funds or Other Consideration

The source and amount of funds used to effect the purchase of the Issuer's common stock and warrants described under Item 5 were personal funds of the Reporting Person in the amount of \$25,000.

Item 4. Purposes of the Transactions

The purpose of the reported, and all previous, acquisitions of the Issuer's Common Stock, together with options to purchase same, is investment without a view, presently or ultimately, to acquiring control of the Issuer. The Reporting Person serves as Chairman of the Board of Directors, President and Chief Executive Officer of the Issuer. In this capacity, the Reporting Person has proposed, and may in the future propose, candidates for election to the Issuer's board of directors.

There is no agreement or arrangement between the Reporting Person and the Issuer with respect to election of candidates proposed by the Reporting Person. The inclusion of such candidates in management's slate of directors to be submitted for consideration by the Issuer's shareholders is entirely at the discretion of the Issuer's board of directors.

CUSIP No. 249827205 Schedule 13D

Item 5. Interest in Securities of the Issuer

The following table sets forth shares of the Issuer's Common Stock as to which the Reporting Person maintains beneficial ownership. The Reporting Person maintains both voting power and dispositive power relative to all such shares:

Beneficial Common Stock Ownership

Owned outright	335,684
Exercisable options (1)	20,000
Exercisable options (2)	40,000
Exercisable options (3)	76,055
Exercisable options (4)	180,000
Exercisable options (5)	24,000
Exercisable options (6)	68 , 750
Exercisable options (7)	25,000
Exercisable warrants (8)	220,001
Exercisable warrants (9)	50,000
Total beneficially owned	1,039,490
	=======
Percentage of class beneficially owned	8.00%

(1)	Exercisable	at	\$4.00	per	share.
(2)	Exercisable	at	\$5.63	per	share.
(3)	Exercisable	at	\$5.93	per	share.
(4)	Exercisable	at	\$0.40	per	share.
(5)	Exercisable	at	\$0.61	per	share.
(6)	Exercisable	at	\$0.37	per	share.
(7)	Exercisable	at	\$1.55	per	share.
(8)	Exercisable	at	\$0.85	per	share.
(9)	Exercisable	at	\$1.05	per	share.

On January 31, 2005 the Reporting Person purchased from the Issuer 50,000 units (the "Units") each consisting of one share of common stock and one four-year warrant to purchase one share of common stock at \$1.05. The Reporting Person and 19 other institutional and individual investors purchased 2,760,000 Units, in the same offering and upon identical terms, for a total investment of \$1,380,000. The foregoing sales and purchases were effected in transactions not involving a public offering.

PAGE 5 CUSIP No. 249827205

Schedule 13D

Item 6. Contracts, Arrangements, Understandings or Relationships with respect to Securities of the Issuer

None

Item 7. Material to Be Filed as Exhibits

None.

Signatures

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

March 7, 2005

POWER OF ATTORNEY INCORPORATED BY REFERENCE

The limited power of attorney dated September 11, 2000 and filed with the Securities and Exchange Commission on September 11, 2000 with Edward J. Quilty's Schedule 13D/A, Amendment No. 4, is incorporated herein by reference.